Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625567 | 0.89 | LMNA (0.48) | LMNAPKMSMN1; SMN2HCRTR1MEN1 | |
| SCHEMBL3610935 | 0.87 | MEN1 (0.56) | TGFBR1LIMK2LMNAPKMSMN1; SMN2 | |
| SCHEMBL3622833 | 0.85 | LMNA (0.65) | TGFBR1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL6751632 | 0.83 | LMNA (0.48) | LMNAPKMSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL3613446 | 0.80 | TGFBR1 (0.49) | TGFBR1MEN1GAAKMT2ACKS1B | |
| SCHEMBL18553798 | 0.79 | TGFBR1 (0.63) | TGFBR1LIMK2LMNAHCRTR1MEN1 | |
| SCHEMBL4513123 | 0.79 | NPY5R (0.48) | LMNASMN1; SMN2ALDH1A1CKS1BSKP1 | |
| SCHEMBL15599357 | 0.77 | BACE1 (0.59) | LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL6603122 | 0.77 | GPR119 (0.46) | CKS1BSKP1SKP2 | |
| SCHEMBL3620496 | 0.77 | HTR6 (0.50) | LMNAPKMSMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | TGFBR1 4130/4885LIMK2 4251/4885LMNA 3478/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | TGFBR1 4130/4885LIMK2 4251/4885LMNA 3478/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | TGFBR1 4414/4885LIMK2 4167/4885LMNA 3475/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | TGFBR1 4414/4885LIMK2 4167/4885LMNA 3475/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | TGFBR1 4414/4885LIMK2 4167/4885LMNA 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.